Artigo Acesso aberto Revisado por pares

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

2017; Elsevier BV; Volume: 131; Issue: 3 Linguagem: Inglês

10.1182/blood-2017-09-806463

ISSN

1528-0020

Autores

Tomáš Pika, Ute Hegenbart, Pavla Flodrová, Bettina Maier, Christoph Kimmich, Stefan Schönland,

Tópico(s)

Chronic Myeloid Leukemia Treatments

Referência(s)
Altmetric
PlumX